Sonedenoson

Drug Profile

Sonedenoson

Alternative Names: MRE-0094

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator New York University
  • Developer King Pharmaceuticals Research and Development
  • Class Anti-inflammatories; Purine nucleosides; Small molecules
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Diabetic foot ulcer

Most Recent Events

  • 26 Feb 2008 Sonedenoson is still in Phase II trials for wound healing in the United States
  • 08 Sep 2005 Phase-II clinical trials in Diabetic foot ulcer in USA (Topical)
  • 15 Jan 2004 King Pharmaceuticals has completed initial dosing in an ongoing phase I trial of topical MRE 0094 for diabetic neuropathic foot ulcers.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top